Dear fellow caregivers and MM sufferers,
I have been using ChatGPT to help me understand blood work and bone marrow results for the last year of treatment, which began with my wife's kidney failure in January of 2025 and the subsequent diagnose of MM. Her recovery has been spectacular with minimal side effects. With help from Chat, I have composed the following letter (a bit long perhaps) in preparation for our January 6th oncologist appointment. Please comment as you see fit, particularly as to whether or not I am being reasonable.
Current Therapy (as of Dec 2025)
• Anti-CD38 monoclonal antibody infusion every 2 weeks
• Lenalidomide 25 mg, days 1–21 of 28-day cycle
• Corticosteroids: weekly oral dexamethasone plus IV methylprednisolone with infusions
• Zoledronic acid monthly
• IVIG monthly for hypogammaglobulinemia
________________________________________
Objective Evidence of Disease Control
Bone Marrow
• No detectable malignant plasma cells
• Hematopoiesis recovered
CBC Trends (Jan–Dec 2025)
• Early severe cytopenias resolved
• Sustained hemoglobin ~13–15 g/dL
• WBC stable
• Platelets fluctuating but largely safe (120–220k)
• Persistent macrocytosis consistent with treatment effect
SPEP / Immunoglobulins
• No rising monoclonal spike
• Persistent hypogammaglobulinemia (gamma globulin ~0.5 g/dL)
• Pattern consistent with treatment-related immune suppression, not progression
Ferritin
• Elevated but declining over time
• Consistent with inflammation/transfusion/steroid exposure rather than disease activity
________________________________________
Clinical Interpretation
• Current laboratory abnormalities are more consistent with cumulative treatment toxicity than active myeloma
• Patient appears to be in a deep, durable response approaching functional remission
• Ongoing full-intensity therapy may be contributing to:
o Immune suppression requiring IVIG
o Cytopenias and macrocytosis
o Steroid-related adverse effects
________________________________________
Proposed Stepwise De-escalation (Risk-Minimizing)
1. Steroids (highest priority)
• Reduce weekly dexamethasone dose by ≥50% or discontinue oral weekly dosing
• Rationale: minimal added disease control in deep responders, high toxicity burden
2. Lenalidomide optimization
• Reduce dose (e.g., 10–15 mg)
• Or modify schedule (e.g., 14 days on / 14 days off)
• Rationale: marrow stress, cytopenias, immune suppression
3. Infusion spacing
• Consider extending monoclonal antibody infusions to every 4 weeks
• Alternatively, trial close-monitoring pause
4. Bone agent reassessment
• Consider spacing zoledronic acid to every 3 months or discontinuation if no active bone disease
5. IVIG reassessment
• Goal: reduce need by allowing immune reconstitution following therapy de-escalation
________________________________________
Monitoring Plan to Mitigate Risk
• Monthly CBC, SPEP, free light chains
• Symptom surveillance
• Rapid re-escalation if biochemical or clinical relapse detected
________________________________________
Key Question for Discussion
Can we preserve disease control while reducing treatment-related toxicity and improving immune recovery through a cautious, stepwise de-escalation strategy?
